The hallmarks of cancer was an attempt to describe the underlying principles 2 of carcinogenesis. In their latest iteration, there is a particular focus on the 3 role that the microenvironment and signalling between cancer cells and their 4 neighbors play in the pathology of tumors. Since the original description of the 5 hallmarks there has been a huge leap forward in our understanding of the 6 biology of cellular senescence promoting it from an autonomous tumor 7 suppressor to a complex, dynamic phenotype that can sometimes be tumor 8 suppressive, but sometimes oncogenic. In particular, our understanding of the 9 diverse non-autonomous effects that senescent cells can have upon both 10 cancer cells and the tumor microenvironment suggests that senescent cells 11 could play a major role in many human cancer types. Here we suggest that 12 cellular senescence could underpin the biology of many of the hallmarks of 13 cancer, making it the true power behind the throne.
Abstract 1
The hallmarks of cancer was an attempt to describe the underlying principles 2 of carcinogenesis. In their latest iteration, there is a particular focus on the 3 role that the microenvironment and signalling between cancer cells and their 4 neighbors play in the pathology of tumors. Since the original description of the 5 hallmarks there has been a huge leap forward in our understanding of the 6 biology of cellular senescence promoting it from an autonomous tumor 7 suppressor to a complex, dynamic phenotype that can sometimes be tumor 8 suppressive, but sometimes oncogenic. In particular, our understanding of the 9 diverse non-autonomous effects that senescent cells can have upon both 10 cancer cells and the tumor microenvironment suggests that senescent cells 11 could play a major role in many human cancer types. Here we suggest that 12 cellular senescence could underpin the biology of many of the hallmarks of 13 cancer, making it the true power behind the throne. 14
INTRODUCTION 1
At the turn of the millennium Hanahan and Weinburg described their 2 hallmarks of cancer to try and distill the essential underlying changes that 3 cells undergo to develop into cancer (Hanahan & Weinberg 2000) . This was 4 an attempt to reduce the vast complexity described in various types and 5 stages of cancer into its six underlying principles. One of these characteristics 6 was the insensitivity to anti-growth signals or the loss of tumor suppressor 7 function; their examples centered on the role of the retinoblastoma protein 8
(RB) and TGF-β as archetypes of autonomous and secreted cytostatic 9 factors, respectively. In the report, the description of senescence amounted to 10 a single reference to the recent identification that unrestricted expression of 11 oncogenic RAS could drive senescence (Serrano et al. 1997) . At the time 12 cellular senescence was seen solely as an autonomous tumor suppressor 13 mechanism, but little was known of its role throughout the life-cycle and its 14 complex non-autonomous signalling. Since the publication of the original hallmarks, it has been the explosion of our 5 understanding of the ability of senescent cells to co-ordinate other players 6 within the tumor microenvironment through secreted signals or cell-contact 7 that suggest that senescence rather than simply being an autonomous tumor 8 suppressor could underpin many of these hallmarks of cancer. Here we take 9
advantage of the hallmarks of cancer (highlighted in 'bold' in the text) to 10 discuss the role of senescence in the development and progression of cancer, 11 in addition to the therapeutic opportunities that senescence presents to treat 12 both cancer and the side-effects of anti-cancer therapies. 13 
14

SENESCENCE AS AN AUTONOMOUS TUMOR SUPPRESSOR 15
Replicative Senescence 16
As 'replicative immortality and sustained proliferative signalling' are 17 hallmarks of cancer, the converse, stable proliferative arrest, is the essential 18 hallmark of senescence. Senescence was first defined in cultured human instability, leading to a modest increase in spontaneous tumor formation in 10 highly proliferative cell types (Rudolph et al. 1999 
Therapy-induced senescence (TIS) 24
In addition to its tumor suppressive role, senescence is also a potential 1 therapeutic goal in fully developed cancer, termed therapy-induced 2 senescence (TIS). The first genetic evidence for in vivo TIS precedes that of 3 the OIS studies: In murine models of lymphoma, when apoptosis is defective, 4
Senescence is distinct from quiescence in terms of the 'irreversible' nature of 1 the proliferative arrest. How is the stability of senescence arrest achieved? 2 This is particularly critical for OIS, which has constitutively 'sustained 3 proliferative signalling'. A number of autonomous effectors potentially 4 contribute to this arrest (Fig. 1b) . It has been shown that mutations causing 5 persistent activation of the RAS pathway provoke a negative feedback 6 response, which inhibits RAS/PI3K pathway in human cells at various levels in years, the recognition that anti-tumoral immunity is actively suppressed 25 through inhibitory immune check-points (such as PD-1 and CTLA4) has led to 1 an explosion in the interest in blocking these mechanisms to release the 2 endogenous anti-cancer function of the patients own immune system. It would 3 be interesting to know whether the SASP is also involved in this process. The opposing effects of the HSC-SASP on HCC development in these two 9 models might be, in part, due to the different metabolic state. The extent of 10 liver damage and fibrosis, the latter appearing absent in the obesity model, 11 might also need to be considered. These factors might affect the nature of the 12 immune microenvironment, particularly at the initial stage of tumorigenesis, 
DISCLOSURE STATEMENT 11
The author is not aware of any affiliations, memberships, funding, or financial 12 holdings that might be perceived as affecting the objectivity of this review. 13 
14
ACKNOWLEDGMENTS 15
We thank members of the Narita lab for comments on this review. Senescence-associated secretory phenotype contributes to pathological 50 suppressor mechanism, but other features serve to promote development and 1 progression of cancer. We summarise these features here in this pseudo-2 heatmap and link them to the hallmarks of cancer in a simplified manner. Premature senescence develops as a consequence of a diverse range of stressors, such as ionising radiation, unrestricted oncogene activation or anti-cancer therapies. The cell-cycle arrest of senescence is underpinned by the p53 / p21 pathway and p16 / RB pathway, which co-operatively contribute to senescence establishment and maintenance. b-c) A current view of the senescence network involving both autonomous (b) and non-autonomous (c) features of senescence. Multiple effector mechanisms contribute to the autonomous senescence phenotype including the DNA-damage response (DDR) and autocrine reinforcement through the senescence-associated secretory phenotype (SASP). Oncogene-induced senescence is often accompanied by senescence-associated heterochromatic foci (SAHF) and negative feedback loops repressing activity of the RAS / MAPK / PI3K pathways. c) Senescence is associated with profound non-autonomous effects upon multiple players within the microenvironment. Either through SASP-paracrine signaling or cell-contact-dependent juxtacrine signaling, senescent cells are able to promote plasticity, modulate immunity (typically inflammatory, but can also be immunosuppressive), fibrosis (typically fibrotic, but can also be fibrolytic), orchestrate tissue repair, drive angiogenesis and, if persistent, drive chronic inflammation. Dependent on the context of the signal-receiving cell, these non-autonomous effects can be tumour suppressive or pro-oncogenic. Dotted lines represent remote activities through secretory factors. 'No arrow head' lines indicate the effect can be either promoting or suppressing. 
